WIRB-Copernicus Group (WCG) announced its acquisition of MedAvante and ProPhase.
WCG is the leading provider of solutions that improve the quality and efficiency of clinical research.
The combined strengths of MedAvante, ProPhase, and WCG will provide expertise and services for those conducting clinical trials in the fields of central nervous system (CNS) and mental health., said Jeffrey Litwin, MD, CEO of MedAvante and Prophase.
The acquisitions position WCG as the frontrunner in the growing behavioral health assessment and CNS markets via the delivery of clinical services and technology solutions that improve signal detection.
WCG will provide a more complete and cohesive suite of study start-up solutions
Crosstree Capital Partners acted as exclusive financial advisor to MedAvante.